Kornimate/medical-research-clean huggingface dataset:
assessment of early changes in sd-oct after initiation of a treatment by intravitreal aflibercept (eylea®)start

Conditions: Neovascular Age-related Macular Degeneration of All Subtypes

Summary: aflibercept (eylea®) induces a rapid reduction in central retinal thickness (crt) for patients suffering from neovascular age-related-macular degeneration.1 this early dramatic reduction in crt is already observed through week 4. therefore it might be not necessary to consistently perform each of the three monthly consecutive intravitreal injections of the so-called loading phase.

the aim of this study is to assess whether the retina of some patients has dried up after the first or second intravitreal injection of aflibercept (eylea®) 2mg and in that event, to determine the proportion of these patients the analysis of the characteristics could help identify a morphotype that would predict whether and when the retina will dry up within the first 3 months of treatment. for some patients having an early drying-up, the third monthly injection might be not necessary 50 naïve patients will be included and will receive a monthly injection over 12 weeks with a biweekly follow-up. morphological and functional characteristics will be recorded at each visit and will be analyzed. the rate of patients with dry sd-oct will be assessed. the study includes 7 visits. the visits are scheduled on an every 2-week basis from baseline to week 12. v1 (baseline), v3 and v5, the patient will be injected with aflibercept (eylea®) 2mg. in the other visits, the visual acuity test, fundus photography, sd-oct, and/or fluorescein angiography are performed

Eligibility criteria:
inclusion criteria: * men and women ≥ 50 years of age * active primary subfoveal choroidal neovascularization (cnv) lesions secondary to amd including juxtafoveal lesions that affects the fovea as evidenced by fa in the study eye * signed informed consent * willing, committed, and able to return for all clinic visits and complete all study-related procedures. exclusion criteria: * prior treatment with anti-vegf therapy in the study eye * active or suspected ocular or periocular infection. * active severe intraocular inflammation

Keywords: wet amd, sd-oct, intravitreal injection, central retinal thickness,
roy adaptation model in people with type 1 diabetes

Conditions: Type 1 Diabetes; Adolescent

Summary: the study was conducted to determine the effect of roy adaptation model-based education on disease compliance and metabolic control in adolescents with type 1 diabetes.

this study was designed as a randomized controlled study. a total of 60 adolescents, training (n=30) and control (n=30) that meet the research criteria were divided by random method. pre-training data of the groups were collected using the "sociodemographic form", "diabetes information evaluation form" and "roy adaptation model interview form" and hba1c values were recorded. the training group was trained on the roy adaptation model by a month break, in two sessions. after the training, the adolescents in the training group were given a curvature booklet based on the roy adaptation model. the control group was not intervened. after the training, the diabetes information assessment form and the roy adaptation model discussion form have applied to both groups again and the values of hba1c were recorded.

Eligibility criteria:
inclusion criteria: 1. having type 1 diabetes 2. must be between the ages of 11-18 3. volunteering for research exclusion criteria 1. presence of mental disability 2. to have received training on the content of the study
efficacy and safety of bai combined with deb-bace of equalspheres in the treatment of advanced nsclc

Conditions: Carcinoma, Non-Small Cell Lung

Summary: this is a prospective, single-arm, open-label study designed to evaluate the efficacy and safety of bronchial infusion chemotherapy（bai） combined with drug-loaded microsphere embolization of equalspheres in advanced non-small cell lung cancer (nsclc). progression-free survival (pfs) will be evaluated as the primary endpoint.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years old, male and female; 2. according to the guidelines for the diagnosis and treatment of primary lung cancer (2022 edition), the patient was diagnosed with nsclc by imaging and histopathology; 3. tnm stages were iii-iv; 4. newly diagnosed, first-line treatment failure, refusal or inability to perform conventional treatment (surgery, chemoradiotherapy); 5. ecog ps ≤2; 6. expected survival \> 3 months; 7. sign the informed consent voluntarily, and the compliance is good. exclusion criteria: 1. previously received interventional therapy (iodine particle implantation, ablation, tace treatment); 2. combined with extensive and uncontrolled extrapulmonary metastases, such as liver metastasis, bone metastasis, and brain metastasis; 3. have had or currently having other primary malignant tumors; 4. white blood cell \< 3×109/l, platelet count \< 50×109/l, hgb \< 90 g/l; 5. hepatic and renal insufficiency (creatinine \> 2 mg/l; ast and/or alt \> 2 times the normal upper limit); 6. coagulation dysfunction (inr \> 1.5) or known bleeding disease (except lung cancer combined with hemoptysis), or anticoagulation therapy; 7. patients with active infection requiring antibiotic treatment; 8. uncontrolled hypertension, diabetes, and cardiovascular disease with obvious symptoms; 9. contrast agent allergy; 10. women with pregnancy or lactation.
fecal microbiota transplantation for radiation-induced proctopathy

Conditions: Radiation Induced Proctitis

Summary: the goal of this single-arm trial is to learn if fecal microbiota transplantation (fmt) works to treat hemorrhagic radiation-induced proctopathy. the main questions it aims to answer are: * dose fmt alleviate the symptom of severe rectal bleeding? * dose fmt improve the endoscopic findings of proctopathy? participants will: * take fecal microbiota capsules by 8 sessions over a 12-week period. * visit the clinic once every 4 weeks for checkups and tests. * keep a diary of their symptoms and the number of times they use other supportive care.


Eligibility criteria:
inclusion criteria: * age: 18-75 years old * at least 3 months since the completion of pelvic radiotherapy * no evidence of tumor recurrence or metastasis * rectal bleeding with grade 2-4 by lent-soma scales * colonoscopy indicating rectal congested mucosa or telangiectasia * poor response to supportive care, or hemoglobin level less than or equal to 70 g/l in the past 3 months exclusion criteria: * acute or chronic infectious diseases * serious systemic diseases * known allergies to any components of the study medication * colonoscopy indicating rectal ulceration (\>1cm2), fistula, stricture, or necrosis * late complications related to pelvic radiation injury * other hemorrhagic or coagulation disorders * previous rectal resection * bowel obstruction or perforation that require surgery * cognitive or psychological disorder * contraindications to fmt administration

Keywords: fecal microbiota transplantation rectal bleeding radiation proctitis
pre-treatment exercises versus post-treatment exercises for dysphagia

Conditions: Head and Neck Cancer

Summary: the purpose of this project is to determine if pre-treatment swallowing exercises can improve post-treatment swallowing function in patients undergoing radiation with or without chemotherapy for advanced squamous cell carcinoma of the head and neck.


Eligibility criteria:
inclusion criteria: * stage iii or iv squamous cell cancer of teh pharynx and larynx * patients who will be receiving chemoradiation * age 19 years of age or older * must sign informed consent. exclusion criteria: * prior cancer diagnosis * metastatic disease * cognitive impairment

Keywords: cancer dysphagia radiation patients with h&n cancer who will be receiving chemoradiation
preterm delivery prevention in twins with progesterone

Conditions: Pregnancies

Summary: twin pregnancies have very high preterm delivery rate. until now, no rct has proven benefit of progesterone in this population. in contrast, singleton pregnancies are treated with this hormone. the objective is to compare 180mg/day progeterone vaginal gel with 180mg/day with placebo, from 18 weeks to 34 weeks. the sample size was calculated and 213 cases in each group are needed to demonstrate a reduction of preterm delivery \<34weeks from 13% to 7%.


Eligibility criteria:
inclusion criteria: * monochorionic or dichorionic twin pregnancies * 18 weeks to 24 weeks at inclusion. exclusion criteria: * cerclage before inclusion * contractions, rupture of the membranes, cervix dilation, * short cervix (15mm or 20mm if there is history of preterm delivery * monoamniotic twins, major malformation, selective iugr, trap, ttts. * younger than 14 years.

Keywords: twin pregnancy progesterone preterm delivery >14 years abscense of cerclage, ttts, hemorrage, history of thrombosis. cervix >15mm
testing tactile aids with blind subjects

Conditions: Vision, Low; Blindness

Summary: the objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. these materials are commonly used in household products, but have not yet been used to enrich tactile aids. successful outcomes are primarily the accuracy with which low vision or blind subjects identify objects made from tactile coatings versus traditional tactile aids. other outcomes include time to completion of the task, or the number of distinctive categories that participants can identify.

traditional images and graphics, like mathematical plots or charts, are not accessible to low vision and blind people. instead, for blind and low vision people, tactile aids are traditionally used to convey abstract concepts. however, tactile aids cannot convey as rich or as dense of information as traditional visual graphics, limiting independence and access to gainful employment for low vision and blind professionals. the primary reason why tactile aids are inferior to visual graphics is that tactile aids are made from a combination of physical bumps, lines, and labels. placing too many details on a single tactile aid quickly becomes illegible to the user because the various bumps, lines, and textures blur together, which is known as "tactile clutter". the objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. these materials are commonly used in household products, but have not yet been used to enrich tactile aids. successful outcomes include having low vision or blind subjects identify objects made from our tactile materials quicker than traditional tactile aids, or to successfully identify more categories on a mathematical plot than is currently possible with existing tactile aids.

Eligibility criteria:
inclusion criteria: * visual impairment: participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired. * tactile aid usage: participants must use tactile aids regularly. * mathematical knowledge: participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry. exclusion criteria: - limb conditions: participants with amputations or outer extremity conditions affecting hand use will be excluded.

Keywords: tactile aid
influenza and pertussis vaccination status of women in immediate postpartum and caregivers

Conditions: Pertussis/Whooping Cough; Influenza Viral Infections

Summary: pertussis is a bacterial respiratory infection caused by bordetella pertussis. highly contagious, it is potentially serious and even fatal in infants under 6 months of age. the immunity acquired through vaccination is very limited in time, requiring regular booster shots. there is a passive protection of the newborn by the maternal-fetal transmission of maternal antibodies, but it is brief. the infant's first vaccination is given at 2 months of age and immunity is not acquired until the second injection at 4 months of age. the booster at 11 months of age is essential to prolong this immunity. in order to protect infants under 6 months of age, france has recommended since 2004 the cocooning strategy, which consists of vaccinating people likely to be in close contact with the infant during this period. this vaccination is therefore proposed to adults who are planning to have children, to the entourage of pregnant women, and in the immediate post-partum period for the mother (and people who were not vaccinated during pregnancy). this strategy was put in place following the international recommendation of a forum of scientific experts, the global pertussis initiative. in france, vaccination against pertussis is not currently recommended during pregnancy. there is no contraindication to vaccination during pregnancy and it is recommended in many countries. influenza is a viral respiratory infection caused by myxovirus influenzae, which is highly contagious. in france, vaccination against influenza is recommended for pregnant women, regardless of the trimester of pregnancy. it is also recommended for the entourage of infants under 6 months of age with risk factors for severe influenza. there are few recent data in the scientific literature regarding influenza and pertussis vaccination coverage among pregnant or postpartum women in france. in addition, the covid19 pandemic has recently reopened the debate on vaccination of the general population and caregivers. knowing the current status of vaccination coverage among pregnant women and caregivers, their knowledge and fears regarding vaccination could help improve the information provided by healthcare staff.


Eligibility criteria:
inclusion criteria: * person having received complete information about the research and not opposed to the study. * hospitalization in the post-partum service and within the last 5 days of delivery. * women. caregivers exclusion criteria: * female under 18 years of age, * woman under legal protection, * delivery of a stillborn child, * premature delivery \< 35ga, * hospitalized newborn, * women who doesn't speak french.

Keywords: immunization cocooning
ecmosorb trial - impact of a va-ecmo in combination with cytosorb in critically ill patients with cardiogenic shock

Conditions: Cardiogenic Shock

Summary: in the ecmosorb study the impact of a veno-arterial -ecmo in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined

the prospective, interventional, randomised controlled and blinded ecmosorb study investigates in critically ill patinets with cardiogenic shock and with veno-arterial ecmo (va-ecmo) treatment the impact of an extracorporeal cytokin hemadsorption system on hemodynamics, defined by the inotropic score 72 hours after initiation of the adsorber (intervention) or normal ecmo tube (control) in the va-ecmo.

Eligibility criteria:
inclusion criteria: * cardiogenic shock of any cause and indication for va-ecmo * age between 18 and 80 * signed informed consent exclusion criteria: * current participation in another interventional trial * pregnancy * current immunosuppressive or immunomodulatory therapy * contraindications to va-ecmo implantation. * patients with pre - existing sepsis (raised cpr, positive pct, leukozytosis, fever, positive blood cultures). * shock duration\> 12 h before evaluation. * severe pvd (peripheral vessel disease) making ecmo-implantation impossible. * aortic valve insufficiency / stenosis at least ii °. * age \> 80 years. * cns disease with fixed, dilated pupils (not drug-induced). * severe concomitant disease with limited life expectancy \<6 months. * cpr\> 60min. * shock due to other reasons * hit positive (heparin induced thrombocytopenia) * very low platelet counts (\< 20,000/µl) * body weight less than 45 kg

Keywords: cardiogenic shock va-ecmo venous arterial extracorporeal membrane oxygenation inotropic score extracorporeal cytokine hemadsorption system cytokine adsorber intensive care multi organ failure
the effects of apomorphine on experimental and clinical pain in patients with chronic radicular pain

Conditions: Chronic Low Back Pain

Summary: the study aimed to explore the effect of the dopamine agonist apomorphine on spontaneous pain intensity and evoked cold clinical and experimental pain in patients with lumbar radicular neuropathic pain (np). patients received either apomorphine or placebo in a randomized double-blinded manner.

although evidence suggests that dopaminergic systems are involved in pain processing, the efficacy of dopaminergic interventions in reducing pain remains questionable. this randomized, double blinded, placebo-controlled, cross-over study was aimed to explore the effect of the dopamine agonist apomorphine on spontaneous pain intensity and evoked cold clinical and experimental pain in patients with lumbar radicular neuropathic pain (np). data was collected from 35 patients (18 men, mean age 56.2±13.1 years). the following five pain measures were tested before (baseline) and 30, 75 and 120 min subsequent to subcutaneous injection of 1.5 mg apomorphine or placebo in two separate sessions: spontaneous pain intensity, threshold and tolerance to cold pain in the most painful site in the affected leg and in a remote healthy site in the dominant hand.

Eligibility criteria:
inclusion criteria: 1. presence of radicular pain for at least 3 months; 2. average pain level during the last week prior to enrollment \> 40 (0-100); 3. no use of a new analgesic drug within 30 days prior to entry to the study and 4. adults who were capable of understanding the purpose and instructions of the study and signing an informed consent. exclusion criteria: 1. pregnancy or breastfeeding; 2. presence of parkinson's disease or any other extra-pyramidal diseases; 3. history of allergy to the investigational drugs: apomorphine or domperidone; 4. history of polyneuropathy and 5. respiratory depression, dementia, psychotic diseases or hepatic insufficiency
ovary syndrome for efficient diagnosis and targeted therapy

Conditions: Polycystic Ovary Syndrome

Summary: objectives: 1. analysis of dna methyl transferases (dnmt1, dnmt3a and dnmt3b) and histone deacetylases (hdac 1,2,3 and sirts) polymorphisms (somatic and germ line variations). 2. analysis of differential mrna and protein expression of epigenetic markers in ovarian tissues obtained from pcos patients. 3. mirna regulated epigenetic mechanisms in pcos 4. epigenetic regulation of endocrine genes in pcos design : a case control study.sample size:200

1. we will take both blood and ovarian tissue samples used to diagnosis. 2. we will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation. 3. small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment.

Eligibility criteria:
inclusion criteria: * all the subjects would be of indian origin (controls \~100, cases \~100). they would be in their reproductive age (18-45 yrs). rotterdam consensus would be used to diagnose pcos and cases will be selected based on it. criteria for the diagnosis of pcos would include oligo-ovulation cycles longer than 35 days or less than 26 days, elevated free testosterone levels (0.5 ng/dl; the cutof level for free testosterone level was the mean±2 sd according to normal levels in controls), oligomenorrhea or amenorrhea. a ferriman-gallwey (fg) score of≥7 would be taken as indicator for the presence of hirsutism. in accordance with the above criteria, polycystic ovary morphology would be determined by transvaginal ultrasonography, which defines pcos as the presence of 12 or more small (2-9 mm) follicles in each ovary. control subjects would have no signs of menstrual dysfunction and their androgen levels should be within the normal range, with normal glucose tolerance, and no family history of hirsutism, type 2 diabetes mellitus, and infertility. exclusion criteria: * women with other causes of hyperandrogenism such as hyperprolactinemia, androgen-secreting tumors, cushing syndrome and nonclassic congenital hyperplasia would be excluded from this study.
3d rotational ct angiogram with embolization guidance and cbct in prostatic artery embolization

Conditions: Enlarged Prostate

Summary: the purpose of this research study is to learn about how cone-beam computerized tomography scans (x-ray images taken from different angles) work together with an embolization guidance software (helps the doctor see the arteries that feed the prostate)to find and see arteries in the prostate.


Eligibility criteria:
inclusion criteria: * patient is age 50 to 79, inclusive * patients undergoing prostate artery embolization for bph or urinary retention -patient has signed informed consent. exclusion criteria: * patients with biopsy proven prostate cancer * patient weight of \>300 lbs

Keywords: bph lower urinary track infection urine retention
the stress reduction intervention study

Conditions: Stress, Physiological; Stress, Psychological

Summary: the primary purpose of the present study is to investigate the relationship between mindfulness and stress habituation. the investigators propose to measure the effect of mindfulness on stress habituation by randomly assigning participants to a 6-week mindfulness-based stress reduction group intervention, a cognitive-behavioral skills group comparison intervention, or a waitlist control condition followed by repeated acute psychosocial stress testing (2 laboratory sessions on 2 separate days). saliva will be collected from participants throughout both laboratory testing sessions to measure hpa axis activation (an essential stress-responsive system), along with other measures of physiological and psychological stress (e.g., heart rate, blood pressure, emotions). mediators and moderators of treatment outcome will be examined. the cognitive-behavioral skills group condition is an appropriate comparison group due to the well-documented efficacy of cognitive-behavioral interventions on stress.


Eligibility criteria:
inclusion criteria: * english-speaking adults who are between the ages of 18-50, who are in general good health * perceived stress scores (pss) \> 3 on a screening survey exclusion criteria: * reported previous completion of a mindfulness-based stress reduction or cognitive behavioral therapy program. * reported pregnancy * reported use of steroid medication * presence of a major psychiatric or endocrine disorder (e.g., major depression, cushings disease; self-reported) * reported regular wake time after 10:00 am on a weekday